Physician profile
Theodore Perl
NPI 1598710378
$4,429.00
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,207 · 2020: $429 · 2021: $657 · 2022: $538 · 2023: $531 · 2024: $67.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $599.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,807.13 | 2019-2023 | Catalys System, Tecnis Iol |
| Eyevance Pharmaceuticals LLC | $380.34 | 2019-2023 | Flarex |
| Kala Pharmaceuticals, INC. | $360.01 | 2020-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $284.53 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $277.12 | 2019-2023 | |
| Dompe US, INC. | $158.75 | 2021-2024 | Oxervate |
| Bausch & Lomb Americas INC. | $157.47 | 2023-2024 | Vyzulta, Envista Mx60 Iol |
| Mallinckrodt Hospital Products INC. | $139.78 | 2020-2023 | Acthar |
| Biotissue Holdings INC. | $123.44 | 2021-2024 | |
| Oyster Point Pharma, INC. | $115.20 | 2022-2023 | Tyrvaya |
| Mallinckrodt Enterprises LLC | $114.32 | 2019 | |
| Sun Pharmaceutical Industries INC. | $102.43 | 2019-2023 | Cequa |
| Ani Pharmaceuticals, INC. | $100.75 | 2022-2023 | Purified Cortrophin Gel |
| Shire North American Group INC | $98.91 | 2019 | |
| Allergan, INC. | $85.19 | 2020-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $38.59 | 2022 | |
| Santen INC. | $20.97 | 2023 | Verkazia |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Ocular Therapeutix, INC. | $15.63 | 2023 | Dextenza |
| Abbvie INC. | $14.73 | 2022 | |
| Sight Sciences, INC. | $14.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Perl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.